Genetic and pharmacological reduction of CDK14 mitigates α-synuclein pathology in human neurons and in rodent models of Parkinson’s disease
Jean-Louis Parmasad(University of Ottawa), Maxime W.C. Rousseaux(University of Ottawa)
Cited by 1
Related Papers
Characterizing the differential distribution and targets of Sumo1 and Sumo2 in the mouse brain
|iScience|2023|12
Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy
|Cell Death and Disease|2024|6
Characterizing the differential distribution and targets of Sumo paralogs in the mouse brain
|bioRxiv (Cold Spring Harbor Laboratory)|2022|2
Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy
|Research Square|2023|1